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Atherosclerosis, cholesterol, nutrition, and statins –
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Atherosklerose, Cholesterin, Ernährung und Statine – eine kritische
Übersicht
Abstract
Atherosclerosis,whichcausesapproximatelyhalfofalldeathsofadults
over age 60 in industrialized nations, is a pandemic among inappropri-
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adults world wide. Although nowadays statins are widely prescribed to
middle age and elderly adults with high blood lipid levels as pharmaco-
logical prevention for the late complications of atherosclerosis, from a
critical point of view statins seem not to solve the problem, especially
when compared with certain natural ingredients of our nutrition like
micronutrients as alternative strategy. Statin ingestion is associated
with lowering of serum cholesterol and low-density lipoprotein concen-
trations; some prospective studies have shown statistical associations
with subsequent modest reduction of mortality from cardiovascular
disease. However, specific biochemical pathways and pharmacological
roles of statins in prevention of atherosclerosis, if any, are unknown.
Moreover, there have been no systematic cost-benefit analyses of life-
style prophylaxis versus statin prophylaxis versus combined life-style
plus statin prophylaxis versus neither life-style nor statin prophylaxis
for clinically significant complications of cardiovascular diseases in the
elderly. Further, in the trialsof effectivenessstatinswere not compared
withmanagementofnutrition,whichisthemostappropriatealternative
intervention.Suchstudiesseemtobeimportant,astheeverincreasing
world population, especially in developing countries, now demand ex-
pensivestatins,whichmaybeunaffordableformitigatingthepandemic.
Studies of this kind are necessary to identify more precisely those pa-
tientsforwhomcardiovascularbenefitswilloutweightherisksandcosts
of the statin treatment in comparison with nutritional interventions.
Against the background of the current pathogenetic concept of athero-
genesissomeofitspossibleriskfactors,particularlytherolesofcholes-
terol and homocysteine, and the effects of statins versus nutritional
(micronutrients)interventionsinpreventionandtreatmentofthedisease
arediscussed.Theprevailingopinionthatserumcholesterolasamedi-
atorofthediseaseis increasedby eatingsaturatedfatsanddecreased
by eatingpolyunsaturated fats is being challenged.Evidently, the bene-
ficial effects of statins in atherosclerosis are not mainly due to its cho-
lesterol lowering effect, rather than to its “pleiotropic effects”. Other
pathogenetic factors in atherosclerosis are involved, like inflammatory
and immunologic processes, that can be modulated by statins as well
asbyotherdrugsorbytheMediterranean-stylenutritionandbymicronu-
trients (folate, B-vitamins).
Keywords: atherosclerosis, nutrition, micronutrients, statins,
homocysteine, lipid-hypothesis, cholesterol, Mediterranean-style
nutrition, B-vitamins, folate, Atorvastatin, Simvastatin
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Review Article OPEN ACCESSZusammenfassung
Die Atherosklerose, etwa für die Hälfte aller Todesursachen der über
60jährigen in den Industrienationen verantwortlich, ist eine Pandemie
unter fehlernährten und/oder körperlich hypoaktiven Kindern, Jugend-
lichen und Erwachsenen. Obwohl heutzutage Statine großzügig für Er-
wachsene im mittleren und hohen Alter mit hohen Blutfettspiegeln als
pharmakologische Prävention der atherosklerotischen Spätfolgen ver-
schrieben werden, erscheinen, kritisch betrachtet, Statine nicht die
Lösung des Problems zu sein, speziell wenn ihre Wirkungen mit denen
natürlicher Nahrungskomponenten, wie Mikro-Nahrungsbestandteile,
alsalternativeStrategieverglichenwerden.DieEinnahmevonStatinen
geht mit einer Senkung des Serumspiegels des Cholesterins und der
Low-density-Lipoproteine(LDL)einher.Hierbeihabeneinigeprospektive
StudienstatistischeZusammenhängemiteinernachfolgendenbeschei-
denen Reduktion der Mortalität kardiovaskulärer Krankheiten gezeigt.
JedochsinddiespezifischenbiochemischenEinflüsseunddiepharma-
kologische Rolle der Statine für die Prävention der Atherosklerose un-
bekannt.ImweiterensindbislangkeinesystematischenKosten-Nutzen-
Analysen der Lifestyle-Prophylaxe versus Statin-Prophylaxe versus
kombinierter Lifestyle- und Statin-Prophylaxe versus weder Lifestyle-
nochStatin-ProphylaxefürklinischbedeutendeKomplikationenkardio-
vaskulärerKrankheitenbeiÄlterendurchgeführtworden.Zudemwurden
die klinischen Studien zur Statinwirkung nicht mit entsprechenden Er-
nährungsmaßnahmen als angemessenster Alternativintervention ver-
glichen. Derlei Studien erscheinen deshalb wichtig zu sein, da die
wachsende Weltbevölkerung, gerade auch in den wirtschaftlichen Ent-
wicklungsländern, jetzt die teuren Statine verlangt, welche aber zur
Eindämmung der Pandemie unerschwinglich sein können. Studien
dieserArtsindfürdiegenauereDefinitionderjenigenPersonennotwen-
dig, für die der kardiovaskuläre Nutzen die Risiken und Kosten der
Statin-TherapievergleichsweisezuErnährungsinterventionenüberwiegt.
Vor dem Hintergrund des heutigen Konzepts der Atherogenese werden
einige ihrer möglichen Risikofaktoren, vor allem die Rolle des Choleste-
rins und Homozysteins, und die Wirkungen der Statine gegenüber von
Ernährungsinterventionen(Mikro-Nahrungsbestandteile)fürdiePräven-
tionundTherapiederKrankheitdiskutiert.DievorherrschendeMeinung,
dass Serum-Cholesterin als Krankheitsmediator mit der Aufnahme von
gesättigtenFettsäurenerhöhtundvonungesättigtenFettsäurenernied-
rigt wird, wird kritisiert. Offensichtlich sind die günstigen Effekte der
StatineaufdieEntwicklungderAtherosklerosehauptsächlichnichtihren
cholesterinsenkenden, sondern eher ihren 'pleiotropen' Wirkungen zu-
zuschreiben.AnderepathogenetischeFaktorensindbeiderAtheroskle-
rose wichtig, wie entzündliche und immunologische Prozesse, die mit
Statinen und anderen Medikamenten oder aber mit mediterraner Er-
nährungsweise und Mikro-Nahrungsbestandteilen (z.B. Folsäure, B-
Vitaminen) moduliert werden können.
Schlüsselwörter: Atherosklerose, Ernährung,
Mikro-Nahrungsbestandteile, Statine, Homozystein, Lipid-Hypothese,
Cholesterin,MediterraneErnährung,B-Vitamine,Folsäure,Atorvastatin,
Simvastatin
Introduction
Strategiestotreatatherosclerosisonlypharmacologically
should take its multifactorial etiology into account
(Figure 1). It may be inadvisable to dwell inordinately
upon lowering serum cholesterol through prophylaxis,
especially since high serum levels of cholesterol may not
be the most important factor in most individuals with the
disease [1], [2].
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Gebbers: Atherosclerosis, cholesterol, nutrition, and statins ...Figure 1: Polyetiology of atherosclerosis: Histology of different states of obstructing atherogenesis surrounded by the known
risk factors
Statins are a recent development; they have become the
stars of the drug industry’s response to coronary artery
atherosclerosis. Worldwide, their annual sales are now
about 30 billion dollars, increasing every year [3]. This is
not only profitable for drug manufacturers but also for
thosewhosecareersdependonfinancingandmarketing
the sales of statins. But does this necessarily translate
into improvement in the overall health of the population?
Questioningstatin-euphoriahasopenedanotherquestion;
for whom should statins be used? Paradoxically, as
knowledgeoftheactionsofstatinshasincreased,rational
answers to the latter question have become increasingly
difficult to find.
The multifactorial pathogenesis of
atherosclerosis
Great progress has been made in identifying risk factors
andpathogeneticalprocessesleadingtoatherosclerosis.
Avarietyofdifferentriskfactors,suchassmoking,hyper-
tensionandshearstress,hypercholesterolemia,diabetes
mellitus,obesity,sedentarylifestyleandaginghavebeen
described, although the impact of each one of those
factors is unknown. All these factors lead to endothelial
activation and/or dysfunction, which can elicit a series
of cellular interactions that culminate in the lesions of
atherosclerosis.
The involvement of vascular endothelium in disease
processes such as atherosclerosis has been recognized
since the time of Virchow [4], but mechanistic insights
into the pathophysiology of this tissue have developed
only recently, largely as a result of application of modern
cellular and molecular biologic techniques [5]. We now
appreciatethatthesingle-cellthickliningofthecirculatory
system is, in fact, a vital organ whose health is essential
tonormalvascularphysiologyandwhosedysfunctioncan
beacriticalfactorinthepathogenesisofvasculartissue.
Thevascularendotheliumisadynamicmutableinterface,
whosestructuralandfunctionalpropertiesareresponsive
toavarietyofstimuli,bothlocalandsystemic,andfurther
more its phenotypic modulation to a dysfunctional state
can constitute a pathogenetic risk factor for vascular
diseases.
Inthevascularwall,certainconsequencesofendothelial
dysfunction are directly related to the pathogenesis of
atherosclerosis and its complications. These con-
sequences include altered vascular reactivity and
vasospasms; altered intimal permeability to plasma
constituents, enhanced mononuclear leukocyte recruit-
ment and intimal accumulation of mononuclear cells;
altered vascular cell growth regulation and survival (e.g.
decreased endothelial regeneration, increased smooth
muscle proliferation, enhanced susceptibility to apop-
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thrombin generation, and platelet and fibrin deposition).
Pathophysiologicalstimuliofarterialendothelialdysfunc-
tion, that are especially relevant to atherosclerosis, in-
clude activation by cytokines and bacterial products; in-
fection by bacteria, viruses, and other pathogens; stimu-
lation by advanced glycation endproducts generated in
diabetes and with aging; chronic exposure to homo-
cysteinemia and accumulation of oxidized lipoproteins
and their components (e.g. lysophosphatidylcholine)
within the vessel wall – all these different factors lead to
a chronic inflammatory process [6].
In addition to these biochemical stimuli, it is now clear
that various biomechanical forces, generated by the
pulsatile flow of blood through the branched arterial
vascular system, can also influence the structure and
function of endothelial cells and even modulate their ex-
pression of pathophysiologically relevant genes [7].
The possibility that hemodynamic forces can act directly
as pathophysiological stimuli for endothelial dysfunction
provides a conceptual rationale for the longstanding ob-
servation that earliest lesions of atherosclerosis charac-
teristicallydevelopinanon-randompattern,thegeometry
of which correlates with branch-points and other regions
of altered blood flow [2], [7], [8].
Of major significance is the fact, that the accumulation
of substantial numbers of monocytes/macrophages and
activated T and B lymphocytes in focal areas of the arter-
ial intima appears to be a hall mark of atherosclerosis –
atherosclerosis is an inflammatory disease induced at
sites of hemodynamic strain in the vascular system [6].
Studies both in humans and in experimental animal
models show an involvement of innate and adaptive im-
mune mechanisms in the disease process manifesting
itself as infiltration and activation of mononuclear cells,
activation of humoral cascade systems, cytokine secre-
tion, cell death, and induction of fibromyoproliferative
processes [6], [9].
A large number of experimental and clinical studies have
established that the immune system plays an important
pathogenetic role in atherosclerosis. Current data imply
innate immunity as necessary for lesion formation and
thishasledinvestigatorstoconcludethatatherosclerosis
isaninflammatorydisease.Theroleofadaptiveimmunity
ismorecomplex–itispresentthroughoutdiseasedevel-
opment and general immune defects reduce the extent
of disease in experimental models. However, specific
defects may have entirely different effects and it is likely
that certain effector mechanisms of adaptive immunity
are proatherogenetic while others may be atheroprotec-
tive.
Attemptstotreatorpreventatherosclerosisbymodulating
immune activity have been successful in experimental
models. Current interest focuses on specific antigens,
such as infectious agents, heat shock protein 60, and
macromolecularcomponentsofChlamydiapneumoniae.
In addition, it is possible that modulation of immunologi-
cally nonspecific inflammatory reactions may be useful
fortreatingatherosclerosis.Finally,inflammatorymarkers
have already proven to be useful for the diagnosis of
active plaques and acute coronary syndromes. All these
data imply that the immune system plays an active role
in atherosclerosis, which can therefore be viewed as an
inflammatory vascular response to a metabolic disturb-
ance [10].
Serum cholesterol and
atherosclerosis
Atherosclerosis, being ubiquitous, develops at all serum
cholesterol levels [1], [2]. Some investigators claimed
that a significant relationship exists between serum
cholesterollevelsandatherosclerosisseverityatautopsy
in the general population, but they failed whether this
has statistical or biological significance [2]. A review of
thesepublicationsconcludedthatnosignificantbiological
relationship existed [11]. It has called attention to the
International Atherosclerosis Project [12] in which corre-
lations varied among the population. The overall correla-
tionwas0.75,butthecholesterolanalyseswerenotfrom
the subjects autopsied [11]. Correlation between athero-
sclerosis severity and animal fat intake was almost zero
and likewise for blood cholesterol and animal fat intake.
The stronger positive correlation with nutritonal animal
protein was ignored because of the preconceived etiolo-
gical importance of nutritonal fat. A study by Strong et al.
[13] reported correlations of 0.26 and 0.36 between
postmortem cholesterol levels and raised lesions in the
aorta and coronary arteries of whites and an explanatory
power of only 6.8% and 13%, respectively. In blacks, the
correlation coefficients were feeble to zero – hardly the
substantive correlation alleged and certainly not sugges-
tive of causality [1], [2].
Despite the strong suspected relationship and current
literature for cholesterol and low-density lipoproteins,
neither the PDAY study (Pathobiological Determinants of
Atherosclerosis in Youth research group) [13], [14] nor
the Framingham Study provided correlation of these
variables with atherosclerosis severity. The PDAY study
[14] measured total cholesterol levels but gave no corre-
lation coefficients for total cholesterol or low-density
lipoproteins, presumably because they were biologically
so weak. They reported only the combined very-low-
density and low-density lipoprotein values, but their con-
tributions were unimpressive and weaker than in a previ-
ous report with fewer subjects [14]. Furthermore, the
results are subject to confounding effects of age, drug
abusage, arteriitis, and failure to exclude subjects with
recognizeddisorders(metaboliclipiddisorders,diabetes
mellitus, hypertension), which should be treated separ-
ately. The pathological and experimental evidence fails
to support a causal relationship between cholesterol,
particularly nutritional cholesterol and atherosclerosis
[1], [2], [11].
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The low-fat nutrition, propagated since years, may even
causemetabolicdisturbances.Pursuinggoodhealthmay
mean including enough fat in the nutrition. Fat that is
either consumed or synthesized de novo in cells is con-
sidered new, whereas old fat is stored in adipose tissue,
waiting to be used. According to Chakravarthy et al. [15],
the liver discriminates between these sources as it co-
ordinates nutrient and energy homeostasis.
Fatty acids serve as the natural ligand for PPARα, a
hepatocytenuclearreceptorthatregulatesgenesinvolved
inthemetabolismofglucose,fattyacids,andcholesterol.
When fed a nutrition with no fat, mice lacking fatty acid
synthase developed hypoglycemia due to a failure in ac-
tivatingtargetgenesofPPARαthatcontrolgluconeogene-
sis.Paradoxically,theliverinthesemicebecamefat-laden
because of the mobilization of peripheral fat and the in-
abilityofthelivertoexpressPPARαtargetgenesinvolved
infattyacidoxidation.Addingnutritionalfatoranagonist
of PPARα reversed these symptoms. Mice lacking fatty
acid synthase also had low serum and liver cholesterol
levels due to decreased hepatic cholesterol synthesis.
The authors propose that new fat may activate a distinct
pool of PPARα in the liver to maintain normal levels of
glucose, fat and cholesterol. Metabolic abnormalities
associated with obesity and diabetes mellitus might be
treated by pharmacologically activating these distinct re-
ceptor pools [15].
Concerning the lipid-atherosclerosis relation, not the
quantity but the quality of serum lipoproteins may be of
particular importance. Recent evidence indicates the
potential preventive pleiotropic effects of high-density-
cholesterol of atherosclerosis [16], [17].
In a short-term study, Mediterranean nutritions were
tested against a low-fat nutrition in randomized 772
asymptomatic adults (age range 55-80 years) with dia-
betesoratleastthreecardiovascularriskfactorstofollow
one of three nutritions: a low-fat nutrition, a Mediter-
raneannutritionthatincluded>30gofvirginoliveoildaily,
orMediterraneannutritionthatincluded>30gofwalnuts,
hazelnuts, and almonds daily. Those on the Mediter-
ranean nutritions received free oil or nuts and were told
to increase their consumption of vegetable fats and oils.
After3months,comparedwiththelow-fatnutrition,each
of the Mediterranean nutritions were associated with
significantly lower mean blood pressure (systolic
6-7 mmHg; diastolic 2-3 mmHg), fasting glucose level
(5-7mg/dL),andtotal-to-HDLcholesterolratio(HDL:high-
density lipoprotein). Weight-loss was similar among the
three groups. Researches could not address clinical out-
comes because of the short term of the study. However,
in terms of effects on cardiovascular risk factors, the
Mediterranean nutritions appeared to be better than a
widely recommended low-fat nutrition [18].
Are statins mainly cholesterol
inhibitors?
Statins are regarded as effective inhibitors of cardiovas-
cular disease because they act directly on inhibiting the
enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA)reductase,whichcatalyzesHMG-CoAtomevalonate,
a rate-limiting step in the biosynthesis of cholesterol. It
was assumed that statin-mediated reductions of blood
cholesterollevelswouldbeassociatedwithcorresponding
reductions in the risks of atherosclerosis-mediated dis-
eases.
However, other mechanisms are at work too, as was
shownbytheWestofScotlandCoronaryPreventionStudy,
inwhichcardiovascularcomplicationsbegantodecrease
within six months after the start of the study, before sig-
nificant lowering of blood cholesterol was observed [19].
A subsequent study of statins in subjects without high
blood cholesterol levels showed that the clinical benefit
of statins was independent of the initial levels of low-
density lipoprotein (LDL) and total cholesterol [20]. One
should also recall that non-statin reducers of blood cho-
lesterol do not reduce the risk of myocardial infarction
asmuchasdostatinswithequivalentreductionsofblood
cholesterol [21]. Despite that, new statins continue to be
advertised as superior blood lipid reducers that yield
clinical benefit through their inhibition of cholesterol
synthesis.
Withtherealizationthatstatinshaveotheractions,atten-
tionhasbeendrawntoendothelialintegrityandfunction.
These depend on various factors including nitrous oxide
(NO)synthesis,vesselwallrelaxivity,inhibitionofvascular
smooth muscle proliferation, leukocyte adherence, and
platelet aggregation. Oxidized LDLs are not only athero-
genic per se, but also inhibit NO-synthetase. Statins act
by lowering LDL and improving endothelial function via
increasedNOandworkalsoviaincreasingNOsynthetase
without inhibiting LDL [22]. Simvastatin enhances the
regeneration of endothelial cells via VEGF secretion in
injured arteries [23]. These findings lead to plausible ex-
planations of the lipid-independence of beneficial statin
effects.
Thisisparticularlyrelevantbecausestatinsdomuchmore
than decrease LDL cholesterol levels. Strong basic sci-
ence evidence also suggests that the effects of statins
oninflammation,thrombosis,andoxidationareplausible
mechanisms for mediating the benefits of statin therapy
often referred to as “pleiotropic effects” [24]. However,
they have not yet led to an adequate appreciation for
whom statins may or may not benefit clinically.
Other substances than statins have been described for
the experimental treatment of atherosclerosis, e.g., the
amine-carboxyborane derivates [25]. In rodents, the
aminecarboxyboraneswerepotenthypolipidemicagents,
lowering both serum cholesterol and triglyceride concen-
trations, in addition to lowering cholesterol content of
very low-density lipoprotein (VLDL) and low-density lipo-
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cholesterol concentrations. De novo regulatory enzymes
involved in lipid synthesis were also inhibited (e.g., hy-
pocholesterolemic 3-hydroxy-3-methyl-Coenzyme A re-
ductase, acyl-Coenzyme A cholesterol acyltransferase,
andsn-glycerol-3-phosphatacyltransferase).Concurrently,
the agents modulated LDL and HDL receptor binding, in-
ternalization, and degradation, so that less cholesterol
wasdeliveredtotheplaquesandmorebrokendownfrom
esters and conducted to the liver for biliary excretion.
Tissuelipidsintheaortawalloftheratwerereducedand
fewer atherosclerotic morphologic lesions were present
in quail aortas after treatment with the agents. Choles-
terolabsorptionfromtheratintestinewasreducedinthe
presence of the drug. Genetic hyperlipidemic mice
demonstratedthesametypesofreductionaftertreatment
with the agents. The agents would effectively lower lipids
in tissue based on the inhibition of regulatory enzymes
in pigs [25].
Like statins, amine-carboxyboranes were shown to be
effective anti-inflammatory agents, e.g., against septic
shock, induced edema, pleurisy, and chronic arthritis at
2.5 to 8 mg/kg. Lysosomal and proteolytic enzyme
activities were also inhibited. More significantly, the
agents were dual inhibitors of prostaglandin-cyclo-oxy-
genaseand5'-lipoxygenaseactivities.Thesecompounds
also affected cytokine release and white cell migration
[25].
Statins as immunomodulators
As mentioned above, atherosclerosis is recognized to
havenotableinflammatoryandimmunologiccomponents
[4], [6], [9], [10], and in parallel, statins appear to have
the ability to inhibit inflammatory processes directly. The
action of statins turns out to be more complex and
broader than was originally expected, and recent studies
have revealed their multiple immunologic actions. The
fact that statins inhibit recruitment and activation of im-
mune-competent cells, such as macrophages, raises the
question whether they may also be beneficial in other
chronic inflammatory conditions and (auto-)immune dis-
eases.
Increasingevidenceindicatesthatsomebeneficialeffects
ofstatinsmayresultfromtheirabilitytomodulatearterial
cell gene expression by mechanisms independent of
cholesterol reduction [26]. Among the first reports of the
immunologic effects of statins was the finding that this
class of drug actually inhibits the interferon-γ (INF-γ)-in-
duced expression of class II major histocompatibility
complex (MHC II) on antigen-presenting cells (APC), and
thus identify a new mechanism by which statins may
modulate immune responses [27]. This inhibitory effect
wasinducedbynano-andmicromolecularconcentrations
ofstatins,particularlyofAtorvastatin,inprimarycultures
of human macrophages and endothelial cells stimulated
with INF-γ. Expression of class I MHC, which activates
cytolyticCD8+T-lymphocytes,wasnotaffectedbystatins
[27].
Selectivemodulationoftheimmuneresponsemayaffect
the progression of atherosclerosis [28]. Two reports
confirm that reducing the inflammatory component of
cardiovascular disease through the use of statin therapy
improvestheclinicaloutcomeindependentlyofthereduc-
tion of serum cholesterol levels [29], [30]. The main
finding of both articles is that a decrease in C-reactive
protein, a marker of inflammation, is independent of the
reductions achieved in LDL-cholesterol levels.
Even in the area of infection, there are findings that
statin therapy has a favourable effect on sepsis and can
reduce the replication of HIV [31].
The notion that the anti-inflammatory effects of statins
amelioratecardiovasculardiseasesuggeststhatitshould
be possible to create other anti-inflammatory agents,
perhaps tailored to the specific immunologic abnormali-
ties in atheroma. Determining the mechanisms of action
ofstatinsandtheirrelativeimportancewillhelptoration-
alize the design of such therapies and nutritions.
Homocysteine, folate, and
atherosclerosis
More than 30 years ago, McCully made the initial clinical
observationlinkingelevatedplasmahomocysteinelevels
with atherosclerotic vascular disease in a post-mortem
review [32]. We now realize that NO synthetase, and
through the latter, endothelial function, are influenced
by a series of factors, among which are micronutrients
suchashomocysteine,amethionine-derivedcomponent
of the nutrition.
Homocysteine is metabolized either reversibly by
methylation,aprocessthatrequiresfolicacidandvitamin
B12 – or irreversibly by loss of cystein, a process that
requires vitamin B6 [33]. Increased plasma concentra-
tions of homocysteine are associated with increased risk
of cardiovascular disease [32], [34], [35]. However,
5-methyltetrahydro-folate,themostimportantcirculating
metabolite of folic acid, acts to increase NO synthesis as
oneofadditionalpositiveeffectscausedbythereduction
ofhomocysteine.Ahighintakeoffolicacidinthenutrition
(5 mg/d) improves endothelial function [36].
Nowadays, hyperhomocysteinemia is a well established,
independent risk factor for the development of athero-
sclerosis. Elevated homocysteine adversely affects arte-
rialendothelialfunction[36],increasesoxidativedamage
and promotes inflammation and thrombosis [35]. There
is a dose-response relationship across a wide range of
homocysteine levels (including so-called normal range)
[36]. A recent study exemplifies this. Amongst >3000
patients with chronic heart disease, a subsequent
coronary event was 2.5 times more likely in patients with
elevated compared to normal serum homocysteine, and
each5μmol/Lofhomocysteinepredicteda25%increase
in risk [37].
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thenutrientsinvolvedinitsmetabolism,particularlyfolate
and vitamins B12 and B6, although other nutrients such
as riboflavin and carnitine also affect it. It has been es-
timated that approximately 2/3 of the prevalence of high
homocysteine is due to low vitamin status [38].
This provides a convincing basis for conducting random-
ised clinical trials using those vitamins to lower homo-
cysteineinordertopreventcomplicationsofatherosclero-
sis like coronary artery disease. It has been quite satis-
factorily demonstrated that homocysteine levels can be
lowered by increasing vitamin intake – in a great many
trials (see recent review [39]), even though some sub-
tleties are not yet fully resolved, such as how much of
which vitamins is the ideal way to reduce homocysteine
levels, the role of genetic variation (MTHFR polymorph-
ism),andtheextenttowhichthehomocysteinereduction
depends on the initial vitamin status.
The lowering of elevated homocysteine plasma levels on
endothelialfunctionhasbeenstudiedandpositiveresults
were reported in 50% of those 21 trials, 41% failed to
detect any improvement, and in 9% the outcome was
borderline significant or independent of homocysteine
reduction [38], [39].
Other trials have found benefits in reduced arterial stiff-
ness,fewerabnormalexerciseECGs,andanon-significant
decrease in cerebrovascular atherosclerosis (measured
by MRI imaging) [39].
A recent study also showed improved intermediary out-
come, i.e. carotid arterial intima-media thickening,
somethingpreviouslyreportedinrenaltransplantpatients
[38]. A related measure, even closer to the ultimate clin-
icalend-points,istherateofrestenosisafterangioplasty.
A homocysteine-lowering supplement decreased such
relapses in over 500 Swiss patients, although in a Ger-
mantrialofover600patients(butwhichusedmuchless
B12) it failed to do so [39].
The Swiss trial mentioned above found a reduced rate of
1yearcompositecardiovasculardiseaseendpoints,and
arecent,small,openprospectiveItaliantrialinhemodia-
lysis patients reported lowered cardiovascular disease
death and mortality from homocysteine reduction [39].
A reanalysis of the VISP trial data identified a sub-set of
2155patients(withoutrenaldiseaseandwithinitialB12
levels likely to respond to supplements) in whom there
was a significant 21% reduction in clinical end points
[39].
One could wonder whether the average pre-treatment
homocysteine levels in some of these trials were high
enough, or the amount of homocysteine reduction ob-
tained was sufficient, or whether the issue is actually the
vitamin levels themselves with homocysteine being only
an indicator. But, as mentioned above, the earlier evi-
dence suggested the homocysteine-cardiovascular dis-
ease link is biological and applies across a broad homo-
cysteine range. It is possible that some combination of
initialvitaminstatusandtreatmentmixcouldexplainthe
positive trial results (for example some authors have fo-
cused specifically on B12 and its absorption in the el-
derly); but this currently remains speculation.
For the moment we cannot say that the data supports
the use of homocysteine-lowering vitamin supplements.
Still,thereducedstrokeincidencefoundinthenewHOPE
2 Study and the positive clinical outcomes from the VISP
sub-set and Swiss trial all need follow-ups. The new
SEARCH(StudyfortheEvaluationofAdditionalReductions
inCholesterolandHomocysteine)trialmayprovidesome
of those answers [40].
It is further recommended the monitoring of B12 and
folate status in the elderly and the consumption of foods
rich in those nutrients. Whether anything is gained from
alsomonitoringhomocysteinelevelsremainsyetunclear.
Apartfromhomocysteinetherecanbeanothergenetically
induced factor, which, however, is not well manipulated
pharmacologically like homocysteine: Lipoprotein a is an
isolated cardiovascular risk factor which can only rarely
be treated pharmacologically by nicotinic acid prepara-
tions. Additional lipid fractions such as apolipoprotein A
and B, who constitute risk factors, can be diminished by
nutrition as well as by statins.
Nutrition and atherosclerosis
The topic is further complicated when we realize that NO
synthetase, and through the latter, endothelial function,
are influenced by a series of factors, as the above men-
tioned homocysteine, a methionine-derived component
of the nutrition [41], [42].
Notonlystatins,butalsoavarietyoffoodingredientscan
influenceendothelialfunctionviacellularNOproduction.
Other components of the nutrition exert anti-atherogenic
effects by different mechanisms. For example, the glit-
azones, components of certain vegetables, inhibit adhe-
sion of leukocytes on damaged endothelium [43].
Afurtherlayerofcomplexitywasuncoveredduringstudies
of diabetes mellitus. In particular, studying the effect of
the statin Simvastatin showed a reduction of risk for
vascular accidents that was independent of the initial
LDL blood cholesterol level [44]. On the other hand, pa-
tients with Type II diabetes mellitus showed no influence
on the reactivity of their vessels to NO when treated in-
tensively with a LDL-lowering drug, Atorvastatin [45] or
Simvastatin [46], both in contrast to folic acid, which re-
gainedNO-dependentvascularreactivity[47].A6-month
study of Atorvastatin for patients with type II diabetes
showed improvement of vascular reactivity unrelated to
anyreductioninLDL[48].Thisimprovementdidcorrelate,
however, with reductions in C-reactive protein, an obser-
vation that led to the postulate that this particular bene-
ficial effect of statin in these patients might be related
tosomeanti-inflammatoryactivityofAtorvastatin.Finally,
further studies showed that Vitamin C supplements im-
proved endothelial-dependent vasodilation in patients
with type I diabetes, but not in healthy control subjects
[49]. Vitamin C inhibits endothelial dysfunction in diabe-
tics in which it improves NO production: it stabilizes and
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NO synthase cofactor tetrahydrobiopterin [50].
Nutrition versus statins
Although they might perturb the research programs of
some established investigators, results like those of the
Lyon Heart Study [51], which showed that improvements
in nutrition led to far better clinical outcomes than did
statintherapyperse,justifyaneedforbetterunderstand-
ing of the anti-atherogenic synergy of nutritional factors
with statins.
Along these lines, a recent study showed that the addi-
tional administration of folic acid was of no additional
benefit for the patients under statin treatment [52].
However,analternativeinterpretationofthisfindingcould
bethatstatinsdidnotresultinadditionalbenefitofthose
who were already taking folic acid nutritional supple-
ments. These matters are currently under scrutiny in
studies that investigate the efficacy of statins and folic
acid in combination or alone, e.g., the SEARCH [40].
Somerecentpublishedstudiesindicateagainthemarked
clinicalbenefitofthe'Mediterraneannutrition'oncardio-
vascularfunction,includingthatoftheelderly[53],which
is associated with improved endothelial function in per-
sons with metabolic syndrome [54].
To determine the extent to which primary and secondary
prevention has contributed to decreased coronary heart
diseasemortalityinEnglandandWalessincethe1980s,
researchers used the IMPACT coronary heart disease
mortalitymodeltosynthesizedatafromnationalsurveys,
official statistics, clinical audits, controlled trials, and
meta-analysis [55]. From 1981 through 2000, age-spe-
cific coronary heart disease mortality fell by 62% in men
and 45% in women, and resulted in about 30,000 fewer
deaths (5000 in people with known coronary heart dis-
easeand25,000inpeoplewithoutthisdisease).Popula-
tion cholesterol levels fell by 4.2%, resulting in about
7900 fewer deaths. Of the 5770 fewer deaths attributed
tonutritionalchanges,about1200wereincoronaryheart
disease patients and about 4500 were in people without
this disease. In contrast, statin treatment was estimated
to have prevented only 1990 deaths in people with
coronaryheartdiseaseand145deathsinpeoplewithout.
Mean population diastolic blood pressure fell by 7.7%,
resulting in 7700 fewer deaths (about 500 in coronary
heartdiseasepatients,5300inhealthypeople,and1900
in hypertensive people). Overall, 81% of averted deaths
were in people without coronary heart disease and 19%
were in those with known disease. The value of these
results is that they integrate several data sources and
indicate that primary prevention contributed more to the
decline in coronary heart disease mortality than did sec-
ondary prevention. The results do not address questions
about cost-effectiveness [55].
Insummary,ifwewanttomakethebestofwhatcommon
micronutrients and statins may offer in the prophylaxis
ofatherosclerosis,weshouldtrytolearnmoreabouthow
to assess the positive effects of statins against their po-
tentialtoxicrisks(neuro-andmyopathies,rhabdomyolysis,
renal tubular necrosis and acute kidney failure) in indi-
vidual patients [56], [57], [58], [59], [60]. Additionally,
titrating lipid-lowering therapy to reduce LDL cholesterol
to very low levels (e.g. <70 mg/dL) by statins can be dif-
ficult, costly, is not without risk and no solid evidence
appears to support this recommendation of the National
Cholesterol Education Program [61].
In a recent study, the potential effect of reducing the in-
take of industrially produced trans fatty acids on the in-
cidence of coronary heart disease in the United states
was calculated [62]. The authors estimated on the basis
of reported relations between trans fat intake and
coronaryheartdiseaseeventsinprospectivestudies10%
to19%ofcoronaryheartdiseaseeventscouldbeaverted
by reducing the intake of trans fat. Thus, given the 1.2
million annual myocardial infarctions and deaths from
coronaryheartdiseaseintheUnitedStates,near-elimina-
tion of industrially produced trans fats might avert
between72,000(6%)and228,000(19%)coronaryheart
diseases each year [62], [63].
The unequivocal beneficial effects of long term caloric
restrictiononthebloodpressure,theratioofcholesterol/
HDL-cholesterol, and the body mass index (BMI), which
have been demonstrated recently [64], [65], must carry
some especially important lessons for public health and
educational policies in our obesity-ridden, low exertion,
industrialized societies, which should surely be at least
asusefultousinthelongrunasistheongoingeducation
of our affluent population about the availability and cost
of prophylactic statins. A recently published hypothesis
indicates the possible fact that statins are analogues of
vitaminD,sinceseveraleffectsofstatinsmatchwellwith
those of that vitamin particularly the anomalous results,
suchasunexpectedbenefitsofstatinslikethemodulation
of inflammations and immune states [66].
Conclusions
Nowadays, we have to face our dependence on results
ofstudiessponsoredbytheindustry,particularlywehave
becometoodependentonmanufacturersasthepredom-
inantsourceofourscientificknowledgeabouttheeffects
of medications [67].
With pharmaceutical costs increasing faster than most
other health care expenditures, we require studies that
will meet the needs of evidence-based presriptions and
treatments and not just the needs of the pharmaceutical
industry.Thesetrialsmustnotonlybeconductedinvolving
combination therapies of the company’s own products
or the test drug against a placebo but rather against nu-
tritional regimens [68]. The conduct of such equivalence
or non-inferiority studies imposes markedly higher meth-
odological demands compared with traditional studies
to prove the superiority of a treatment vs. placebo or
standard therapy. It is not a question of whether we can
afford to pay for our own drug and nutritional trials; it is
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[67].
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